Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors

CALGARY, Canada, September 30, 2010 - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces
that Mr. Kenneth Zuerblis has been appointed to the Company's Board of
Directors. Recently Mr. Zuerblis served as the Chief Financial Officer and
Senior Vice President of ImClone Systems Inc., prior to its acquisition by
Eli Lilly.

"I was initially attracted to Resverlogix because of RVX-208, its novel
atherosclerosis drug, which is a very exciting mid-stage therapeutic gaining
worldwide scientific acceptance. Resverlogix is also developing a pipeline of
novel therapeutics in several disease categories that have significant unmet
medical needs. I look forward to this opportunity to work with members of the
Board of Directors and management as we develop the full potential of the
Company's product candidates," Mr. Zuerblis commented.

Donald J. McCaffrey, President & CEO of Resverlogix, stated, "Ken is a
seasoned veteran in the biotechnology industry with a proven track record of
running complex commercial and research organizations and we are delighted
that he has joined our Board of Directors." In an effort to maintain a Board
of Director level at six people Mr. Wayne Chiu will be stepping down from the
Board effective today. Wayne has been on the Board since its inception and
has been an important contributor to the growth and development of
Resverlogix. The Board expresses its thankfulness to Wayne for his years of
contributions.

Kenneth J. Zuerblis biography

Mr. Zuerblis previously served as Chief Financial Officer and Senior Vice
President of ImClone Systems, a biopharmaceutical company developing biologic
medicines in the area of oncology, from 2008 through 2009 at which time he
helped lead the sale of the company to Eli Lilly for $6.6 billion USD. Prior
to joining ImClone, Mr. Zuerblis served as Chief Financial Officer of Enzon
Pharmaceuticals Inc. from 1994 through 2005 and Corporate Controller from
1991 through 1994. He began his career at KPMG, LLP, in 1982, ultimately
serving as Senior Manager prior to his departure in 1991. Mr. Zuerblis
previously served as a member of the Board of Directors of XTL
Biopharmaceuticals, Ltd., and is a member of the Board of Directors of
Immunomedics and the New Jersey Technology Council. He received a BS in
Accounting from Seton Hall University and is a certified public accountant in
the State of New Jersey.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet medical needs. The NexVas(TM) PR program is the Company's
primary focus which is to develop novel small molecules that enhance ApoA-1.
These vital therapies address the burden of atherosclerosis and other
important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's
disease, Peripheral Artery Disease and other vascular disorders. Resverlogix
Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For
further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as
defined under applicable Canadian securities legislation, including our
statements with respect to research, development and commercialization of
novel therapeutics that reduce the risk of cardiovascular disease including
atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and
other vascular diseases. These forward-looking statements contained herein
that are not based on historical fact, including without limitation
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate", "forecasts"
and other similar expressions. Our actual results, events or developments
could be materially different from those expressed or implied by these
forward-looking statements. We can give no assurance that any of the events
or expectations will occur or be realized. By their nature, forward-looking
statements are subject to numerous known and unknown risks and uncertainties
including but not limited to those associated with the success of research
and development programs, clinical trial programs including possible delays
in patient recruitment, the regulatory approval process, competition,
securing and maintaining corporate alliances, market acceptance of the
Company's products, the availability of government and insurance
reimbursements for the Company's products, the strength of intellectual
property, financing capability, the potential dilutive effects of any
financing, reliance on subcontractors and key personnel and additional risk
factors discussed in other documents we file from time to time with
securities authorities, which are available through SEDAR at
www.sedar.com. Additionally, risks and uncertainties are discussed in
detail in the July 31, 2010 MD&A. The forward-looking statements contained in
this news release are expressly qualified by this cautionary statement are
made as of the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update or revise
any forward-looking statements, whether as a result of new information,
future events or otherwise. The TSX Exchange does not accept responsibility
for the adequacy or accuracy of this news release.

For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: +1-403-254-9252, Email: Theresa@resverlogix.com; US
Institutional Investors: Susan Noonan, Managing Partner, S.A. Noonan
Communications, LLC, Phone: +1-212-966-3650, Email: Susan@sanoonan.com

For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1-403-254-9252, Email: Theresa at resverlogix.com; US Institutional Investors: Susan Noonan, Managing Partner, S.A. Noonan Communications, LLC, Phone: +1-212-966-3650, Email: Susan at sanoonan.com